Literature DB >> 20190717

Prediction severity of esophageal varices: a new cutoff point for Platelet count/ spleen diameter ratio.

R Barikbin1, A Hekmatnia, N Omidifar, M Farghadani, P Adibi.   

Abstract

AIM: It is currently recommended that all patients with liver cirrhosis undergo upper gastrointestinal endoscopy (UGIE) to identify those who have esophageal varices (EV) that carry a high risk of bleeding and may benefit from prophylactic measures. In the future, this social and medical burden will increase due to the greater number of patients with chronic liver disease and their improved survival. The aim of this paper was assess value of platelet count/spleen diameter ratio (PC/SD ratio) for the prediction or screening of EV in cirrhotic patients.
METHODS: In this two years prospective study, patients with liver cirrhosis referred to Al -Zahra hospital enrolled. Patients underwent detailed clinical examination, blood tests (hematology, liver function tests) and ultrasonography. Size of esophageal varices was assessed at UGIE; Paquet's grades 0-III were classified as group A (0-I; No or Mild EV) and group B (II-III; Moderate to severe EV). PC/SD ratio was also measured as possible noninvasive predictive/screening tools. Degree of eEV was assessed at UGIE. The relationship of the presence and degree of EVs with PC/SD ratio was evaluated.
RESULTS: Fifty consecutive cirrhotic patients (mean age+/-SD) was 52.1 (+/-16.2); 41 male and 9 female) were enrolled; nineteen 19 (38%) patients were placed in group A (No or mild EV) while 31 (62%) had endoscopic evidence of moderate to severe EV (group B). PC/SD ratio cut off value of 921 had 93% negative predictive value. PC/SD ratio found to be significantly (P<0.05) different between group of A and B.
CONCLUSIONS: The PC/SD ratio is independently associated with the presence of EV and can predict its severity in patients with cirrhosis. Use of this cost effective parameter may help identify patients with mild or no EV who may not need UGIE to reduce costs and discomfort for these patients and the burden on health system.

Entities:  

Mesh:

Year:  2010        PMID: 20190717

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  6 in total

Review 1.  Performance of platelet count/spleen diameter ratio for diagnosis of esophageal varices in cirrhosis: a meta-analysis.

Authors:  Li Ying; Xiao Lin; Zuo-Liu Xie; Yuan-Ping Hu; Ke-Qing Shi
Journal:  Dig Dis Sci       Date:  2012-02-26       Impact factor: 3.199

Review 2.  Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.

Authors:  Agostino Colli; Juan Cristóbal Gana; Jason Yap; Thomasin Adams-Webber; Natalie Rashkovan; Simon C Ling; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2017-04-26

3.  Towards noninvasive detection of oesophageal varices.

Authors:  Kara Rye; Robert Scott; Gerri Mortimore; Adam Lawson; Andrew Austin; Jan Freeman
Journal:  Int J Hepatol       Date:  2012-03-14

Review 4.  Platelet Count to Spleen Diameter Ratio for the Diagnosis of Gastroesophageal Varices in Liver Cirrhosis: A Systematic Review and Meta-Analysis.

Authors:  Runhua Chen; Han Deng; Xia Ding; Chune Xie; Wei Wang; Qian Shen
Journal:  Gastroenterol Res Pract       Date:  2017-02-08       Impact factor: 2.260

5.  Usefulness of Noninvasive Predictors of Oesophageal Varices in Black African Cirrhotic Patients in Côte d'Ivoire (West Africa).

Authors:  Alassan Kouamé Mahassadi; Fulgence Yao Bathaix; Constant Assi; Aboubacar Demba Bangoura; Emile Allah-Kouadio; Henriette Ya Kissi; Abdoulaye Touré; Stanislas Doffou; Issa Konaté; Alain Koffi Attia; Mathieu Benoit Camara; Thérèse Aya Ndri-Yoman
Journal:  Gastroenterol Res Pract       Date:  2012-07-22       Impact factor: 2.260

6.  Doppler surrogate endoscopy for screening esophageal varices in patients with cirrhosis.

Authors:  Kambiz Akhavan Rezayat; Fariborz Mansour Ghanaei; Ahmad Alizadeh; Afshin Shafaghi; Ali Babaei Jandaghi
Journal:  Hepat Mon       Date:  2014-01-16       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.